Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis in Residual Diabetic Macular Edema
NCT01472510Phase 2Completed
- Sponsor
- Vitreo Retinal Associates
- Start
- Dec 2011
- Primary completion
- Jul 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in diabetic macular edema (DME), sponsored by Vitreo Retinal Associates. Started Dec 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01472510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01472510.